{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T10:10:37Z","timestamp":1773655837542,"version":"3.50.1"},"reference-count":20,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Lenvatinib is an oral multi-kinase inhibitor which is used for the treatment of renal cell carcinoma, non-iodine avid differentiated thyroid cancer, hepatocellular carcinoma, and endometrial cancer. We present a series of three (3) patients who, whilst on treatment with Lenvatinib, developed symptoms and radiological findings of acalculous cholecystitis. A radiological review of another nineteen (19) Lenvatinib-treated patients in our center was undertaken, with another three (3) patients exhibiting radiological features of acalculous cholecystitis with gallbladder wall thickening and pericholecystic fluid collection but without abdominal pain or clinical symptoms of cholecystitis. A literature review is also presented of all previous publications of Lenvatinib-induced acalculous cholecystitis, including the results of two pharmacovigilance studies. This review provides evidence that Lenvatinib-induced acalculous cholecystitis is not as rare as initially thought from the Lenvatinib licensing studies; hence, this is an adverse event that merits more attention. Oncologists using Lenvatinib should be aware of this potential toxicity and be familiar with its management.<\/jats:p>","DOI":"10.3390\/curroncol33030167","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T08:41:26Z","timestamp":1773650486000},"page":"167","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lenvatinib-Induced Acalculous Cholecystitis\u2014An Often-Unrecognized Toxicity: A Case Series and Literature Review"],"prefix":"10.3390","volume":"33","author":[{"given":"Christos","family":"Cortas","sequence":"first","affiliation":[{"name":"German Oncology Center, 4108 Limassol, Cyprus"},{"name":"Bank of Cyprus Oncology Center, 2006 Nicosia, Cyprus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Symeonidou","sequence":"additional","affiliation":[{"name":"Bank of Cyprus Oncology Center, 2006 Nicosia, Cyprus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6518-1936","authenticated-orcid":false,"given":"Haris","family":"Charalambous","sequence":"additional","affiliation":[{"name":"Bank of Cyprus Oncology Center, 2006 Nicosia, Cyprus"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Matsui","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"A Randomised Phase 3 Trial of Lenvatinib vs. Sorafenib in First-line Treatment of Patients with Unresectable Hepatocellular Carcinoma","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_6","unstructured":"(2024, June 22). Summary of Product characteristics\u2014Lenvima (Lenvatinib)-Eisai co. Available online: www.ema.europa.eu."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2169\/internalmedicine.3806-19","article-title":"Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib","volume":"59","author":"Honda","year":"2020","journal-title":"Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s12328-020-01116-5","article-title":"Lenvatinib-induced acute acalculous cholecystitis in a patient with hepatocellular carcinoma","volume":"13","author":"Ishigaki","year":"2020","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/MD.0000000000027182","article-title":"Incidence and Computed Tomography findings of Lenvatinib-induced Pancreatobiliary inflammation A single-center, Retrospective Study","volume":"100","author":"Kurokawa","year":"2021","journal-title":"Medicine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000510369","article-title":"High Prevalence and Conservative Management of Acute Cholecystitis during Lenvatinib for Advanced Thyroid Cancer","volume":"10","author":"Colombo","year":"2021","journal-title":"Eur. Thyroid. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/thy.2019.0355","article-title":"Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem","volume":"30","author":"Nervo","year":"2020","journal-title":"Thyroid"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/EJE-19-0763","article-title":"Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data","volume":"182","author":"Aydemirli","year":"2020","journal-title":"Eur. J. Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/bcp.15243","article-title":"Cholecystitis and cholangitis associated with lenvatinib: A pharmacovigilance study","volume":"89","author":"Lu","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1080\/14740338.2024.2393284","article-title":"A real-world drug safety surveillance study of lenvatinib from the FAERS database","volume":"24","author":"Yang","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.beha.2009.01.001","article-title":"Thrombosis associated with angiogenesis inhibitors","volume":"22","author":"Elice","year":"2009","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4251\/wjgo.v4.i5.115","article-title":"A case of severe acalculous cholecystitis associated with sorafenib treatment for advanced hepatocellular carcinoma","volume":"4","author":"Aihara","year":"2012","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"201529","DOI":"10.5402\/2011\/201529","article-title":"Acalculous cholecystitis in a patient with hepatocellular carcinoma on sorafenib","volume":"2011","author":"Sanda","year":"2011","journal-title":"ISRN Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1053\/j.gastro.2005.12.034","article-title":"Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism","volume":"130","author":"Gaudio","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.beem.2017.04.012","article-title":"Management of Tyrosine Kinase Inhibitors (TKI) Side Effects in Differentiated and Medullary Thyroid Cancer Patients","volume":"31","author":"Resteghini","year":"2017","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cgh.2009.08.034","article-title":"Acute acalculous cholecystitis: A review","volume":"8","author":"Huffman","year":"2010","journal-title":"Clin. Gastrenterol. Hepatol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/3\/167\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T09:33:31Z","timestamp":1773653611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/3\/167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["curroncol33030167"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33030167","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]}}}